Sangui Biotech International, Inc.
SGBI · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -52.8% | 152.2% | 40.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 40.7% | 69.1% | 36% | 1.9% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | $0 | -$0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -28.7% | 103.1% | -38.1% | 1.9% |
| EPS | -0 | 0.001 | -0 | 0 |
| % Growth | -114.3% | 800% | -3,433.3% | – |
| EPS Diluted | -0 | 0.001 | -0 | 0 |
| Weighted Avg Shares Out | 211 | 210 | 211 | 238 |
| Weighted Avg Shares Out Dil | 210 | 210 | 210 | 210 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | -$0 | -$0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 0% | 0% | 0% | 2.1% |